Inclusion Criteria:

          -  Classic or endemic histologically confirmed Kaposi Sarcoma (KS) that is progressive,
             but does not require a systemic therapy ;

          -  Injectable and measurable disease, defined as:

               -  At least 2 cutaneous lesion ≥10mm in its largest diameter, in a not previously
                  irradiated field;

               -  At least 2 other cutaneous lesion ≥10mm in their largest diameter available for
                  repeated cutaneous biopsies, in a not previously irradiated field.

               -  Clusters of small lesions with edge to edge distance <2 mm, if the biggest
                  diameter of each cluster meet the 2 previous criteria.

          -  Be willing to provide tissue from cutaneous biopsy;

          -  At least 4 weeks washout for all KS specific therapies including topical treatment,
             chemotherapy, radiotherapy and immunotherapy including interferon;

          -  Provide written, informed consent prior to the performance of any study specific
             procedures;

          -  Be more than 18 years of age on day of signing informed consent.

          -  Have a performance status of 0 or 1 on the ECOG Performance Scale.

          -  Demonstrate adequate organ function:

               -  Haematological : Absolute neutrophil count (ANC) ≥1500/mm3; Platelets ≥100
                  000/mm3; haemoglobin≥ 8 g/dL;

               -  Renal: Serum creatinine ≤ 1.5 x upper limit of normal (ULN), OR calculated
                  creatinine clearance ≥ 40mL/min for subject with creatinine levels > 1.5 x ULN.

               -  Hepatic: AST (SGOT) and ALT (SGPT) ≤ 2.5xULN, serum total bilirubin ≤ 1.5xULN OR
                  direct bilirubin ≤ ULN for subjects with total bilirubin levels >1.5xULN.

               -  PT≤1.5; PTT (TCA) ≤1.5

          -  Female subject of childbearing potential should have a negative serum pregnancy within
             72 hours prior to receiving the first dose of study medication

          -  Have a health insurance.

        Exclusion Criteria:

          -  Known history of organ transplantation or HIV (HIV 1/2 antibodies detected at
             selection);

          -  Symptomatic visceral involvement of KS including brain metastases;

          -  Active autoimmune disease that requires systemic treatment (i.e. with use of disease
             modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy
             (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for
             adrenal or pituitary insufficiency, etc.) is not considered a form of systemic
             treatment. Patients with vitiligo, type I diabetes mellitus, hypothyroidism, psoriasis
             non requiring systemic treatment are permitted to enrol;

          -  Evidence of clinically significant immunosuppression such as the following: primary
             immunodeficiency state such as Severe Combined Immunodeficiency Disease; concurrent
             opportunistic infection;

          -  Receiving systemic immunosuppressive therapy including oral steroid doses > 10 mg/day
             of prednisone or equivalent within 7 days prior to enrolment;

          -  Active herpetic skin lesions or prior complications of HSV-1 infection (eg, herpetic
             keratitis or encephalitis);

          -  Intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic
             drug (eg, acyclovir), other than intermittent topical use;

          -  Previous treatment with talimogene laherparepvec or any other oncolytic virus;

          -  Prior radiotherapy in which the fields overlap the injection sites;

          -  Prior immunosuppressive, chemotherapy, radiotherapy, biological cancer therapy, or
             major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1
             or better from adverse event due to KS therapy administered more than 28 days prior to
             enrollment.

          -  Prior therapy with tumor vaccine;

          -  Received live vaccine within 28 days prior to enrolment;

          -  Currently treatment with another investigational device or drug study, or less than 28
             days since ending treatment with another investigational device or drug study(s);

          -  Acute or chronic active hepatitis B (HbS Ag detected) or C infection (HCV RNA
             detected) at inclusion;

          -  Known additional malignancy that is currently progressing or requires active treatment
             within the last 3 years. Exceptions include basal cell carcinoma of the skin or
             squamous cell carcinoma of the skin that has undergone potentially curative therapy or
             in situ cervical cancer;

          -  Sensitivity to any of the products or components to be administered ;

          -  Psychiatric or substance abuse disorders that would interfere with cooperation with
             the requirements of the trial;

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial and 3 months after the last dose of talimogene
             laherparepvec;

          -  Subjects who are unwilling to minimize exposure with his/her blood or other body
             fluids to individuals who are at higher risks for HSV-1 induced complications such as
             immunosuppressed individuals, individuals known to have HIV infection, pregnant women,
             or infants under the age of 3 months, during talimogene laherparepvec treatment and
             through 30 days after the last dose of talimogene laherparepvec.

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial.

          -  Female subject of childbearing potential who are unwilling to use acceptable method(s)
             of effective contraception during study treatment and through 3 months after the last
             dose of talimogene laherparepvec.

          -  Sexually active subjects and their partners unwilling to use male or female latex
             condom to avoid potential viral transmission during sexual contact while on treatment
             and within 30 days after treatment with talimogene laherparepvec.